Key Moments
#30 – Thomas Seyfried, Ph.D.: Controversial discussion—cancer as a mitochondrial metabolic disease?
Peter Attia MDKey Moments
Revolutionary insight: Cancer is a metabolic disease, not genetic, treatable by targeting glucose and glutamine.
Key Insights
Cancer's primary cause is mitochondrial metabolic dysfunction, not genetic mutations, leading cells to rely on fermentation even with oxygen (Warburg Effect).
Cancer cells exhibit structural and functional defects in mitochondria, forcing them to use substrate-level phosphorylation for energy, fueled by glucose and glutamine.
Metabolic therapies, like calorie-restricted ketogenic diets combined with compounds like hyperbaric oxygen and glutamine inhibitors, selectively starve cancer cells while sparing normal cells.
Conventional cancer treatments, particularly radiation and corticosteroids, can exacerbate the disease by promoting inflammation and supplying tumor fuel.
Needle biopsies may increase the risk of metastasis due to inflammatory processes, suggesting a need for non-invasive diagnostic and pre-surgical tumor reduction strategies.
Glioblastoma Multiforme (GBM) exemplifies the failures of current treatments; metabolic therapies offer a potential for significantly increased survival and higher quality of life by addressing the core metabolic defect.
THE BIOLOGY BEHIND METABOLIC THERAPIES
Thomas Seyfried proposes a controversial yet compelling perspective on cancer, asserting that it is primarily a mitochondrial metabolic disease rather than a genetic one. His interest began during his work on epilepsy and lipid storage diseases at Yale, where he explored ketogenic diets for seizure amelioration. This led to the discovery that caloric restriction played a key role in managing seizures by lowering blood glucose and elevating ketones. Seyfried extrapolated this understanding to cancer, theorizing that similar metabolic manipulation could be therapeutic by exploiting cancer cells' reliance on specific fuels.
REVIVING THE WARBURG EFFECT: FERMENTATION AS THE CORE MECHANISM
A central tenet of Seyfried's hypothesis is the reinterpretation of the Warburg Effect. Otto Warburg observed that cancer cells preferentially use fermentation (anaerobic glycolysis) for energy, even in the presence of oxygen, a phenomenon termed aerobic glycolysis. Seyfried argues that this is not merely a preference but a necessity, stemming from defective mitochondrial respiration. Cancer cells exhibit structural and functional impairments in their mitochondria, forcing them to rely on less efficient fermentation pathways, predominantly fueled by glucose and glutamine, for survival and proliferation. This metabolic shift is crucial for their disordered growth.
CHALLENGING THE GENETIC PARADIGM OF CANCER
Seyfried directly challenges the prevailing genetic theory of cancer, which posits that accumulated mutations in the nuclear genome are the primary drivers of oncogenesis. He cites instances where cancer cells show no significant genetic abnormalities despite aggressive growth, and conversely, cells with numerous mutations that never develop into tumors. From his perspective, genetic mutations are often downstream consequences or 'epiphenomena' resulting from damaged mitochondrial function and the reactive oxygen species (ROS) produced by impaired respiration. The fundamental issue, he asserts, remains at the metabolic level within the mitochondria.
METABOLIC FUELS: GLUCOSE AND GLUTAMINE
According to Seyfried, cancer cells are critically dependent on two primary fermentable fuels: glucose and glutamine. Unlike normal cells, which can efficiently switch between various fuel sources including ketones, cancer cells struggle to metabolize ketones due to their defective mitochondria. The strategy, therefore, involves systematically reducing the availability of glucose and glutamine to cancer cells while simultaneously enhancing the metabolic flexibility of normal cells. This creates a competitive disadvantage for the tumor, making it vulnerable to elimination without harming healthy tissues.
SUBSTRATE-LEVEL PHOSPHORYLATION: THE CANCER CELL'S ENERGY BACKUP
A key mechanism by which cancer cells generate energy when oxidative phosphorylation is compromised is through mitochondrial substrate-level phosphorylation (SLP). While normal cells use SLP sparingly, tumor cells upregulate this ancient, less efficient ATP production pathway within the mitochondria. This process, disconnected from the electron transport chain, allows cancer cells to bypass their respiratory defects and obtain sufficient ATP to maintain life and continue proliferating. Targeting the substrates for SLP—glucose and glutamine—thus becomes paramount for disrupting tumor energetics.
THE ROLE OF CARDELIPIN AND MITOCHONDRIAL STRUCTURE
Seyfried's research highlights cardiolipin, a signature lipid in the inner mitochondrial membrane, as a critical factor in mitochondrial function. He found that cardiolipin is often defective in tumor cells, directly impacting the electron transport chain and leading to impaired oxidative phosphorylation. This structural defect further supports his argument that a compromised respiratory system, rather than specific genetic mutations, is the root cause of cancer. Morphological abnormalities in mitochondria, visible through electron microscopy, serve as direct evidence of this underlying dysfunction.
PRESS-PULSE THERAPY: A STRATEGIC METABOLIC APPROACH
Seyfried advocates for a 'press-pulse' metabolic therapy strategy. This involves continuously 'pressing' down glucose levels through calorie-restricted ketogenic diets and potentially drugs, while 'pulsing' glutamine-targeting drugs. The 'press' creates a sustained metabolic environment that starves cancer cells and promotes the health of normal cells (which can utilize ketones). The 'pulse' involves short, intense deprivation of glutamine, followed by repletion, to kill glutamine-dependent tumor cells while allowing recovery of glutamine-dependent normal immune and gut cells.
THE PERILS OF CONVENTIONAL TREATMENTS
A significant critique from Seyfried targets conventional cancer treatments, particularly radiation and corticosteroids. He argues that radiation can cause further damage to the brain, leading to radiation necrosis and potentially exacerbating tumor spread, rather than curing it. Corticosteroids, commonly used to reduce brain edema in GBM patients, elevate blood sugar, thereby providing more fuel for cancer cells. Moreover, anti-angiogenic drugs like Avastin, by targeting blood vessels, paradoxically force cancer cells into more hypoxic and invasive states, facilitating metastasis.
THE MACROPHAGE-CANCER FUSION HYPOTHESIS
Seyfried introduces the controversial 'macrophage-cancer cell fusion' hypothesis to explain metastasis. He suggests that neoplastic cells, in conjunction with macrophages (immune cells), fuse together. Macrophages, being highly fusogenic and migratory, provide the combined hybrid cell with the capacity for increased invasiveness and spread throughout the body. The chronic inflammation and hypoxic microenvironment created by fermenting tumor cells attract macrophages, which, instead of resolving the 'wound,' may inadvertently contribute to the tumor's metastatic potential through this fusion process.
RETHINKING GBM TREATMENT: A CASE FOR METABOLIC THERAPY
Glioblastoma Multiforme (GBM) serves as a stark example of the failures of current oncology, with survival rates largely unchanged since 1926. Seyfried believes that GBM, with its aggressive and uniformly fatal nature, is an ideal candidate for demonstrating the efficacy of metabolic therapies. He proposes a protocol involving immediate surgical debulking, followed by sustained metabolic therapy (ketogenic diet, hyperbaric oxygen), and crucially, without immediate radiation and corticosteroids. Anecdotal cases of long-term GBM survivors who rejected conventional treatments support this alternative paradigm.
OVERCOMING BARRIERS TO METABOLIC ONCOLOGY
A major challenge for advancing metabolic cancer treatment lies in overcoming institutional resistance, particularly within regulatory bodies like Institutional Review Boards (IRBs) and funding agencies. These entities are often entrenched in the genetic paradigm, making it difficult to conduct clinical trials for metabolic therapies as primary or sole treatments. Seyfried emphasizes the need for a paradigm shift in thinking, advocating for a holistic approach that embraces metabolic oncology as a legitimate and potentially curative branch of cancer treatment, alongside conventional methods, rather than as a last resort.
Mentioned in This Episode
●Supplements
●Products
●Software & Apps
●Companies
●Organizations
●Books
●Drugs & Medications
●Studies Cited
●Concepts
●People Referenced
Common Questions
Thomas Seyfried's interest in cancer originated during his postdoc at Yale University, where his work on epilepsy and lipid storage diseases led him to examine brain tumors and ultimately the metabolic differences in cancer cells. He got hands-on experience by observing a glioblastoma tumor resection and then studying brain tumors in mice.
Topics
Mentioned in this video
Where Thomas Seyfried earned his PhD in genetics and biochemistry.
Mentioned as the institution where Bud Veatch conducted research on fasting.
Where Thomas Seyfried is currently a professor and conducts his research on metabolic therapies for chronic diseases, including cancer.
A foundation through which Thomas Seyfried's lab receives grants for their research.
Where Thomas Seyfried did his postdoc in the Department of Neurology and began his work on epilepsy and later cancer.
Where George Cahill conducted his research on diabetes and fasting.
Mentioned as having opened a branch of medicine called Cancer Survivor Medicine, addressing the long-term effects of conventional cancer treatments.
A foundation to study epilepsy and ketogenic diets, started by Jim Abrahams.
Provides support for Thomas Seyfried's research program on metabolic therapy for cancer.
Professional American football team for whom Joel Maroon serves as team surgeon.
Renowned biochemist who observed that cancer cells continue to ferment even in the presence of oxygen, a phenomenon known as the Warburg effect.
Mentioned as someone whose research is starting to see the potential applications for metabolic therapies in cancer.
Chief of Neurosurgery at Yale University at the time, who invited Thomas Seyfried to observe glioblastoma removal surgery.
From Hopkins, a researcher who collaborated and found defects in the number, structure, or function of mitochondria in all cancer cells, supporting Warburg's theory.
Late Stanford researcher known for his work on insulin resistance and the insulin suppression test.
Peter Attia's 'trusty right-hand guy' who lives in Boston and takes a course from Thomas Seyfried.
Collaborator with Thomas Seyfried who proposed the theory of substrate-level phosphorylation in cancer.
Started the first school of neuropathology in the United States at Yale University in the 1930s; his work on mouse brain tumors was foundational for Seyfried's research.
Thomas Seyfried's PhD student who informed him about the growing interest in ketogenic diets for epilepsy.
A young GBM patient who rejected conventional treatments, underwent delayed surgery after metabolic therapy, and is alive and well four years later with documented recovery.
A prostate cancer oncologist who collaborated with Seyfried and D'Agostino on the 'press pulse' therapy.
Mentioned as someone whose research is starting to see the potential applications for metabolic therapies in cancer, known for his work on cellular building blocks.
Worked at the Joslin Diabetes Center and studied therapeutic fasting and starvation, providing data on long-term fasted individuals and the Bobby Sands hunger strike.
Co-author of a paper proposing that the Warburg effect is for cellular building blocks, not just energy, and stated respiration in cancer cells is normal.
Collaborated with George Cahill and Thomas Seyfried on studies of therapeutic fasting at the NIH.
Host of the podcast, who has a background in oncology and is interested in metabolic approaches to cancer.
French chemist and microbiologist known for the 'Pasteur effect,' describing how yeast stop fermenting in the presence of oxygen.
Scientists who discovered DNA as the origin of genetic material, shifting the scientific focus away from Warburg's metabolic theory.
One of the Irish prisoners who starved to death as part of a protest, whose blood work data was collected by George Cahill.
Guest on the podcast, a Professor at Boston College with a PhD in genetics and biochemistry, known for his work on cancer as a metabolic disease.
Actress who made the movie 'First Do No Harm,' based on Jim Abrahams' experience with his son and ketogenic diets.
A patient who survived glioblastoma without conventional treatment and has a website sharing her story.
Mentioned as a friend of Peter Attia and a collaborator with Thomas Seyfried on ketogenic diets and cancer.
American politician who suffered from glioblastoma multiforme.
Thomas Seyfried's mentor at Yale University, who conducted research on ganglioside changes in tumors.
Referred to as the 'Godfather of ketogenic diets,' instrumental in saving Jim Abrahams' son Charlie and founding the Charlie Foundation.
Movie director whose son Charlie was saved by ketogenic diets, leading to the creation of the Charlie Foundation.
A patient with stage three astrocytoma who rejected radiation and chemo, underwent surgery, and is still doing well years later with metabolic therapy.
Neurosurgeon and team surgeon for the Pittsburgh Steelers, who collaborated with Seyfried and D'Agostino on the 'press pulse' therapy.
A very aggressive and uniformly fatal brain cancer (grade four astrocytoma) mentioned as a primary focus of metabolic therapies.
The observation that cancer cells preferentially use glycolysis (fermentation) for energy production even in the presence of adequate oxygen, a fundamental concept in Thomas Seyfried's metabolic theory of cancer.
The termination of fermentation in the presence of oxygen, a principle cancer cells violate according to Warburg.
A movie based on Jim Abrahams' experience with his son and ketogenic diets for epilepsy.
Key enzyme in the electron transport chain, whose discovery earned Warburg a Nobel Prize.
An isoform of pyruvate kinase that contributes to the Warburg effect by making lactic acid but not much ATP.
A therapeutic strategy proposed by Seyfried to manage cancer by consistently 'pressing' glucose levels with diet and drugs, and 'pulsing' glutamine inhibition to selectively kill tumor cells without harming normal tissues.
A hormone acting as an appetite suppressor by affecting the vagus nerve.
Used in an Egyptian patient's metabolic therapy along with EGCG.
An old drug that effectively blocks glutamine metabolism and is suggested as a key component of the 'press-pulse' therapy, with reduced toxicity when combined with a ketogenic diet.
An anti-angiogenic drug criticized by Seyfried for potentially increasing the invasive behavior of tumor cells, especially in brain cancer, despite being a blockbuster drug.
More from Peter Attia MD
View all 322 summaries
135 min381‒Alzheimer’s disease in women: how hormonal transitions impact the brain, new therapies, & more
9 minIs Industrial Processing the Real Problem With Seed Oils? | Layne Norton, Ph.D.
13 minCooking with Lard vs Seed Oils | Layne Norton, Ph.D.
146 min380 ‒ The seed oil debate: are they uniquely harmful relative to other dietary fats?
Found this useful? Build your knowledge library
Get AI-powered summaries of any YouTube video, podcast, or article in seconds. Save them to your personal pods and access them anytime.
Try Summify free